Bolus infusion of clotting factor concentrates remains the most common approach to the treatment or prevention of bleeding in patients with hemophilia. Although successful use of continuous infusion of such concentrates has been reported by several groups, this alternative treatment method has not a
β¦ LIBER β¦
The feasibility of using concentrates containing factor IX for continuous infusion
β Scribed by SAM SCHULMAN; SANFORD GITEL; ARIELA ZIVELIN; OLGA KATSAROU; TITIKA MANDALAKI; DAVID VARON; URI MARTINOWITZ
- Book ID
- 108769245
- Publisher
- John Wiley and Sons
- Year
- 1995
- Tongue
- English
- Weight
- 646 KB
- Volume
- 1
- Category
- Article
- ISSN
- 1351-8216
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
The use of continuous infusion of factor
β
Dr Robert D. Bona; Ralph A. Weinstein; Steven J. Weisman; Ann Bartolomeo; Freder
π
Article
π
1989
π
John Wiley and Sons
π
English
β 458 KB
Treatment of hemophilia b: Serendipitous
β
Jonathan C. Goldsmith; E.Maria Gordon
π
Article
π
1993
π
Elsevier Science
π
English
β 235 KB
The Use of Factor IX Concentrates for Pa
β
Doris MΓ©nachΓ©; Marie Claude Gunllin
π
Article
π
1975
π
John Wiley and Sons
π
English
β 786 KB
The argument for using high purity Facto
β
C.A. LEE
π
Article
π
2008
π
John Wiley and Sons
π
English
β 213 KB
The Preparation for Therapeutic Use of a
β
Ethel Bidwell; J. M. Booth; G. W. R. Dike; K. W. E. Denson
π
Article
π
1967
π
John Wiley and Sons
π
English
β 872 KB
Stability and sterility of a recombinant
β
Belgaumi, Asim F.; Patrick, Christian C.; Deitcher, Steven R.
π
Article
π
1999
π
John Wiley and Sons
π
English
β 129 KB
π 2 views
## Minipumps may facilitate cost-effective and convenient continuous infusion (CI) therapy for severe hemophilia A. This study evaluated the in vitro sterility, ability to support bacterial growth, and specific activity stability of a recombinant factor VIII (FVIII; Bio-clateβ’, Centeon) delivered